Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Shah NP, et al. Among authors: khoroshko n. J Clin Oncol. 2008 Jul 1;26(19):3204-12. doi: 10.1200/JCO.2007.14.9260. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541900 Clinical Trial.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. Kantarjian H, et al. Among authors: khoroshko n. Blood. 2007 Jun 15;109(12):5143-50. doi: 10.1182/blood-2006-11-056028. Epub 2007 Feb 22. Blood. 2007. PMID: 17317857 Free article. Clinical Trial.
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Kantarjian H, et al. Among authors: khoroshko n. Blood. 2009 Jun 18;113(25):6322-9. doi: 10.1182/blood-2008-11-186817. Epub 2009 Apr 15. Blood. 2009. PMID: 19369231 Free PMC article. Clinical Trial.
[Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
Zaritskiĭ AIu, Lomaia EG, Vinogradova OIu, Druzhkova GA, Kolosheĭnova TI, Loria SS, Pospelova TI, Krylova IV, Kruglov SS, Kuznetsov SV, Chelysheva EIu, Abakumov EM, Sokolova MA, Nemchenko IS, Zakharova ES, Goriacheva SR, Kolosova LIu, Vakhrusheva MV, Liamkina AS, Chernova OA, Machiulaĭtene ER, Ivanova VL, Udal'eva VIu, Shneĭder TV, Ogorodnikova IuS, Zhuravlev VS, Zakharova AV, Martynkevich IS, Domracheva EV, Afanas'ev BV, Abdulkadyrov KM, Kovaleva LG, Khoroshko ND, Turkina AG. Zaritskiĭ AIu, et al. Among authors: khoroshko nd. Ter Arkh. 2007;79(8):17-22. Ter Arkh. 2007. PMID: 17926465 Clinical Trial. Russian.
[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG, Kruglov SS, Druzhkova GA, Domracheva EV, Zakharova AV, Vinogradova OIu, Sysoeva EP, Diachenko LV, Chelysheva EIu, Zakharova ES, Abakumov EM, Kolosheĭnova TI, Kolosova LIu, Ivanova TV, Zhuravlev VS, Nemchenko IS, Zingerman BV, Kurova ES, Triputen' NZ, Loriia SS, Kovaleva LG, Khoroshko ND. Turkina AG, et al. Among authors: khoroshko nd. Ter Arkh. 2005;77(7):42-7. Ter Arkh. 2005. PMID: 16116908 Russian.
[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases].
Turkina AG, Domracheva EV, Vorontsova AV, Aseeva EA, Vinogradova OIu, Stakhina OV, Gusarova GA, Diagileva OA, Semenova EA, Vakhrusheva MV, Kolosheĭnova TI, Abakumov EM, Chelysheva EIu, Goriacheva SR, Ivanova TV, Zakharova ES, Kolosova LIu, Zakharova AV, Naumova IN, Diachenko LV, Kulikov SM, Kovaleva LG, Khoroshko ND. Turkina AG, et al. Among authors: khoroshko nd. Ter Arkh. 2009;81(7):29-36. Ter Arkh. 2009. PMID: 19708570 Russian.
[The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].
Parovichnikova EN, Savchenko VG, Isaev VG, Sokolov AN, Kulikov SM, Kliasova GA, Ryzhko VV, Kravchenko SK, Khoroshko ND, Konstantinova TS, Zagoskina TP, Ziuzgin IS, Rekhtman GB, Moskov VI, Sokolova IV, Anchukova LV, Lapin VA, Loginov AB, Tumakov VA, Korobkin AV, Miliutina GI, Samoĭlova OS, Mal'tsev VI, Pristupa AS, Men'shakova SN, Domnikova NP, Gavrilova LV, Obidina NA, Porokhina OV, Kaplanov KD, Medvedeva LI, Khuazheva NK, Pilipenko GI, Golubeva ME, Maksimov AG, Ploskikh MA, Khlevnaia NV. Parovichnikova EN, et al. Among authors: khoroshko nd. Ter Arkh. 2007;79(7):14-9. Ter Arkh. 2007. PMID: 17802784 Clinical Trial. Russian.
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
Lipton JH, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, Brummendorf T, Yoo K, Bergstrom B; Pegasys CML Study Group. Lipton JH, et al. Among authors: khoroshko n. Leuk Lymphoma. 2007 Mar;48(3):497-505. doi: 10.1080/10428190601175393. Leuk Lymphoma. 2007. PMID: 17454589 Clinical Trial.
96 results